HIVNCT02761200
Post Analytic Treatment Interruption Study
An observational study of HIV, run by SEARCH Research Foundation at 1 site in Thailand.
Trial summary
This exploratory study is designed to ensure the safety of HIV-infected volunteers who complete research protocols that include an analytic treatment interruption (ATI). This is a prospective cohort study of volunteers who were diagnosed with HIV during early acute HIV infection, treated with antiretroviral therapy… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- HIV
- How many people
- 100 participants
- Where
- 1 siteThailand
- Study dates
- Mar 2016to Mar 2031
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: This study will recruit adults aged 18 years and older at the time of documented acute HIV infection (Fiebig stage I to V) and initiation of ART in Bangkok, Thailand, who have completed clinical research protocols that included analytic treatment interruption (ATI).
Who may be able to join
- Man or woman aged ≥18 years.
- Enrolled in RV254 study.
- Completed clinical research protocol that included ATI within one month of enrollment in this protocol.
- Able and willing to provide written informed consent or, in the case of illiteracy, witnessed verbal informed consent with documentation of a thumbprint in lieu of a signature.
- Able to participate in study visits for up to 144 weeks.
- Willing to have photo or fingerprint taken for identification purposes.
- Female-specific criteria: Agrees not to become pregnant while not receiving ART. If a woman is sexually active and has no history of hysterectomy or tubal ligation or menopause, she must agree to engage in abstinence, use a prescription birth control method or use a barrier birth control method while not receiving ART.
Who cannot join
- History of a medical or psychiatric condition that, in the opinion of investigator, would jeopardize the safety or rights of the subject, such as a condition that would interfere with or serve as a contraindication to adherence to the study protocol or ability to give informed consent.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Somchai Sriplienchan, MD, MPH contact
Nitiya Chomchey, PhD contact
Thailand1 site, 1 recruiting
- Recruiting
SEARCH
Bangkok, Bangkok, 10330
Nittaya - Phanuphak, MD, PhD, +6622542566, nittaya.p@trcarc.org
Nitiya - Chomchey, MSc, +6622542566 ext. 111, nitiya.c@searchthailand.org
About this study
Official title: Safety and Virologic Outcomes After HIV Remission Trials in Patients Who Initiated Antiretroviral Therapy During Early Acute HIV Infection
This exploratory study is designed to ensure the safety of HIV-infected volunteers who complete research protocols that include an analytic treatment interruption (ATI). This is a prospective cohort study of volunteers who were diagnosed with HIV during early acute HIV infection, treated with antiretroviral therapy (ART) and subsequently enrolled in a clinical study that included ATI. After completion of study participation that involves ATI, participants will be recruited into this study for continued clinical and laboratory monitoring.
Read the detailed description
This exploratory study is designed to ensure the safety of HIV-infected volunteers who complete research protocols that include an analytic treatment interruption (ATI). This is a prospective cohort study of volunteers who were diagnosed with HIV during early acute HIV infection, treated with antiretroviral therapy (ART) and subsequently enrolled in a clinical study that included ATI. After completion of study participation that involves ATI, participants will be recruited into this study for continued clinical and laboratory monitoring. Participants without any indication for resumption of ART and who desire to remain off ART at the time of entry into this study will be monitored closely for HIV viremia and other pre-defined criteria for ART resumption. Participants with any indication for ART at the time of enrollment into this protocol, including patient preference for resumption of ART, will be monitored closely for virologic and immunologic response to ART.
Clinical study visits will take place at the Thai Red Cross AIDS Research Centre, and the optional procedures may occur at the King Chulalongkorn Memorial Hospital. Required laboratory studies that are outlined in this protocol will occur in lieu of those described in the RV 254 protocol. Volunteers may provide separate informed consent for optional procedures to include collection of genital secretions, colon biopsy, inguinal lymph node biopsy, cerebrospinal fluid (CSF) collection via lumbar puncture, and brain Magnetic Resonance Imaging (MRI)/Magnetic Resonance Spectroscopy (MRS)/Diffusion Tensor Imaging (DTI). With separate informed consent, willing participants will undergo archival of peripheral blood mononuclear cells and plasma specimens for research purposes.
This study will enroll volunteers aged 18 years and older who have completed clinical studies that include ATI in Bangkok, Thailand. Enrollment in this study will be concurrent with completion of the study with ATI. Participants will fall broadly into one of two categories: those on ART and those not on ART at the completion of the prior study protocol.
The ongoing parent study, RV 254 (SEARCH 010, WRAIR 1494), enrolls participants with documented acute HIV infection at the Thai Red Cross AIDS Research Center in Bangkok, Thailand. Participants in the cohort are primarily men who have sex with men, but also include men and women with other HIV acquisition risk factors as well as various ages, incomes, and education levels. All participants in RV 254 are offered ART at the time of enrollment through a separately funded protocol. Participants in this substudy will remain co-enrolled in RV254/SEARCH010, but will follow the schedule of event (SOE) for this sub-study in lieu of the parent study SOE.
- Conditions
- HIV
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| volunteer who completion of a recent ATI | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Antiretroviral therapy (ART) resumption for any reason
Measured: 96 weeks
Secondary outcomes (4)
Viral suppression after ART resumption
Measured: 48 weeks
Time to viral rebound, from cessation of ART
Measured: 96 weeks
Level of viral rebound after cessation of ART
Measured: 96 weeks
Detectable HIV RNA via single copy assay at various timepoints, such as weeks 48 and 96 off ART, as compared to baseline prior to ATI
Measured: 48 and 96 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 May 2016 (estimated)
- Study startMar 2016
- Primary completionMar 2031 (estimated)
- Study completionMar 2031 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HIVStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- SEARCH Research Foundation
- Sponsor type
- University, hospital or other
- Collaborators
- US Military HIV Research Program
- Responsible party
- Principal investigator, Somchai Sriplienchan, MD, SEARCH Research Foundation
- Investigators
- Somchai Sriplienchan, MD, MPH, Principal investigator, SEARCH Research Foundation
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02761200
- Sponsor's protocol ID
- SEARCH 025/RV412
- Status last verified
- Apr 2026
- First submitted
- 25 Apr 2016
- Last updated
- 27 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 27 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Safety and Virologic Outcomes After HIV Remission Trials in Patients Who Initiated Antiretroviral Therapy During Early Acute HIV Infection
- ClinicalTrials.gov ID
- NCT02761200
- Acronym / sponsor ID
- SEARCH 025/RV412
- Conditions
- HIV
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- SEARCH Research FoundationUniversity, hospital or other
- Collaborators
- US Military HIV Research Program
- Study start
- Mar 2016
- Primary completion
- Mar 2031 (estimated)
- Study completion
- Mar 2031 (estimated)
- First posted
- 4 May 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This exploratory study is designed to ensure the safety of HIV-infected volunteers who complete research protocols that include an analytic treatment interruption (ATI). This is a prospective cohort study of volunteers who were diagnosed with HIV during early acute HIV infection, treated with antiretroviral therapy (ART) and subsequently enrolled in a clinical study that included ATI. After completion of study participation that involves ATI, participants will be recruited into this study for continued clinical and laboratory monitoring.
Detailed description
This exploratory study is designed to ensure the safety of HIV-infected volunteers who complete research protocols that include an analytic treatment interruption (ATI). This is a prospective cohort study of volunteers who were diagnosed with HIV during early acute HIV infection, treated with antiretroviral therapy (ART) and subsequently enrolled in a clinical study that included ATI. After completion of study participation that involves ATI, participants will be recruited into this study for continued clinical and laboratory monitoring. Participants without any indication for resumption of ART and who desire to remain off ART at the time of entry into this study will be monitored closely for HIV viremia and other pre-defined criteria for ART resumption. Participants with any indication for ART at the time of enrollment into this protocol, including patient preference for resumption of ART, will be monitored closely for virologic and immunologic response to ART.
Clinical study visits will take place at the Thai Red Cross AIDS Research Centre, and the optional procedures may occur at the King Chulalongkorn Memorial Hospital. Required laboratory studies that are outlined in this protocol will occur in lieu of those described in the RV 254 protocol. Volunteers may provide separate informed consent for optional procedures to include collection of genital secretions, colon biopsy, inguinal lymph node biopsy, cerebrospinal fluid (CSF) collection via lumbar puncture, and brain Magnetic Resonance Imaging (MRI)/Magnetic Resonance Spectroscopy (MRS)/Diffusion Tensor Imaging (DTI). With separate informed consent, willing participants will undergo archival of peripheral blood mononuclear cells and plasma specimens for research purposes.
This study will enroll volunteers aged 18 years and older who have completed clinical studies that include ATI in Bangkok, Thailand. Enrollment in this study will be concurrent with completion of the study with ATI. Participants will fall broadly into one of two categories: those on ART and those not on ART at the completion of the prior study protocol.
The ongoing parent study, RV 254 (SEARCH 010, WRAIR 1494), enrolls participants with documented acute HIV infection at the Thai Red Cross AIDS Research Center in Bangkok, Thailand. Participants in the cohort are primarily men who have sex with men, but also include men and women with other HIV acquisition risk factors as well as various ages, incomes, and education levels. All participants in RV 254 are offered ART at the time of enrollment through a separately funded protocol. Participants in this substudy will remain co-enrolled in RV254/SEARCH010, but will follow the schedule of event (SOE) for this sub-study in lieu of the parent study SOE.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| volunteer who completion of a recent ATI | – | – |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- This study will recruit adults aged 18 years and older at the time of documented acute HIV infection (Fiebig stage I to V) and initiation of ART in Bangkok, Thailand, who have completed clinical research protocols that included analytic treatment interruption (ATI).
Key inclusion criteria (7 listed)
- Man or woman aged ≥18 years.
- Enrolled in RV254 study.
- Completed clinical research protocol that included ATI within one month of enrollment in this protocol.
- Able and willing to provide written informed consent or, in the case of illiteracy, witnessed verbal informed consent with documentation of a thumbprint in lieu of a signature.
- Able to participate in study visits for up to 144 weeks.
Key exclusion criteria (1 listed)
- History of a medical or psychiatric condition that, in the opinion of investigator, would jeopardize the safety or rights of the subject, such as a condition that would interfere with or serve as a contraindication to adherence to the study protocol or ability to give informed consent.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Antiretroviral therapy (ART) resumption for any reason
Time frame: 96 weeks
4 secondary outcomes
Viral suppression after ART resumption
Time frame: 48 weeks
Time to viral rebound, from cessation of ART
Time frame: 96 weeks
Level of viral rebound after cessation of ART
Time frame: 96 weeks
Detectable HIV RNA via single copy assay at various timepoints, such as weeks 48 and 96 off ART, as compared to baseline prior to ATI
Time frame: 48 and 96 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Apr 2026.
- Individual participant dataSharing planned: Undecided
Related trials for HIV
Recruiting
The Trans-Led Care Study
Substance Abuse, Substance Addiction
RecruitingObservational study
Clinical and Immunologic Monitoring of Patients With Known or Suspected HIV Infection
HIV
RecruitingObservational study
Olfactory Function and Model-Based Behavior in People Living With HIV and SUD
HIV, Substance Use Disorder
RecruitingPhase 1
AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study")
AIDS-Related Diffuse Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
RecruitingObservational study
Leukapheresis Procedures to Obtain Plasma and Lymphocytes for Research Studies on Antiretroviral Naive HIV-1 Research Participants
HIV
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Somchai Sriplienchan, MD, MPH contact
Nitiya Chomchey, PhD contact
Somchai Sriplienchan, MD, MPH principal investigator
SEARCH Research Foundation
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of HIV, run by SEARCH Research Foundation at 1 site in Thailand.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 27 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Thailand. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Somchai Sriplienchan, MD, MPH (somchai.s@searchthailand.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Antiretroviral therapy (ART) resumption for any reason (time frame: 96 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Apr 2026.